Abstract
Relationship between biological responses and binding affinities at I1/I2/I3 imidazoline receptors of compounds with imidazoline, pyrroline or oxazoline moieties was studied by 2D-QSAR, 3D-QSAR and quantitative pharmacophore development approaches. Since the I1 imidazoline receptor is involved in central inhibition of sympathicus that produce hypotensive effect, the I2 receptor is allosteric modulator of monoamine oxidase B (MAO-B) and the I3 receptor regulates insulin secretion from pancreatic β-cells, design and synthesis of selective I1/I2/I3 imidazoline ligands are very important for the development of new effective therapeutic agents. New agonists and antagonists with high selectivity for I1/I2/I3 imidazoline receptor classes have been recently synthesized and examined. The present review will highlight the main chemical diversity and pharmacophore features of selective I1/I2/I3 imidazoline receptor ligands.
Keywords: I1-imidazoline receptors, I2-imidazoline receptors, I3-imidazoline receptors, hypotensive, enzymes, phenylethanolamine-Nmethyl, imidazoline, imidazole-4-acetic, agmatine, lipophilicity
Mini-Reviews in Medicinal Chemistry
Title:Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands
Volume: 12 Issue: 14
Author(s): Katarina Nikolic and Danica Agbaba
Affiliation:
Keywords: I1-imidazoline receptors, I2-imidazoline receptors, I3-imidazoline receptors, hypotensive, enzymes, phenylethanolamine-Nmethyl, imidazoline, imidazole-4-acetic, agmatine, lipophilicity
Abstract: Relationship between biological responses and binding affinities at I1/I2/I3 imidazoline receptors of compounds with imidazoline, pyrroline or oxazoline moieties was studied by 2D-QSAR, 3D-QSAR and quantitative pharmacophore development approaches. Since the I1 imidazoline receptor is involved in central inhibition of sympathicus that produce hypotensive effect, the I2 receptor is allosteric modulator of monoamine oxidase B (MAO-B) and the I3 receptor regulates insulin secretion from pancreatic β-cells, design and synthesis of selective I1/I2/I3 imidazoline ligands are very important for the development of new effective therapeutic agents. New agonists and antagonists with high selectivity for I1/I2/I3 imidazoline receptor classes have been recently synthesized and examined. The present review will highlight the main chemical diversity and pharmacophore features of selective I1/I2/I3 imidazoline receptor ligands.
Export Options
About this article
Cite this article as:
Nikolic Katarina and Agbaba Danica, Pharmacophore Development and SAR Studies of Imidazoline Receptor Ligands, Mini-Reviews in Medicinal Chemistry 2012; 12 (14) . https://dx.doi.org/10.2174/138955712803832636
DOI https://dx.doi.org/10.2174/138955712803832636 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
Call for Papers in Thematic Issues
Bioprospecting of Natural Products as Sources of New Multitarget Therapies
According to the Convention on Biological Diversity, bioprospecting is the exploration of biodiversity and indigenous knowledge to develop commercially valuable products for pharmaceutical and other applications. Bioprospecting involves searching for useful organic compounds in plants, fungi, marine organisms, and microorganisms. Natural products traditionally constituted the primary source of more than ...read more
Computational Frontiers in Medicinal Chemistry
The thematic issue "Computational Frontiers in Medicinal Chemistry" provides a robust platform for delving into state-of-the-art computational methodologies and technologies that significantly propel advancements in medicinal chemistry. This edition seeks to amalgamate top-tier reviews spotlighting the latest trends and breakthroughs in the fusion of computational approaches, including artificial intelligence (AI) ...read more
Natural Products and Dietary Supplements in Alleviation of Metabolic, Cardiovascular, and Neurological Disorders
Metabolic disorders like diabetes, obesity, inflammation, oxidative stress, cancer etc, cardiovascular disorders like angina, myocardial infarction, congestive heart failure etc as well as neurological disorders like Alzheimer?s, Parkinson?s, Epilepsy, Depression, etc are the global burden. They covered the major segment of the diseases and disorders from which the human community ...read more
Natural Products in Drug Discovery
Natural products have always been one of the important ways of drug discovery due to their novel skeleton and diverse functional group characteristics. According to statistics, between 1981 and 2019, the FDA approved a total of 1,394 small molecule drugs for marketing, of which 930 marketed drugs originated from the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Vaccination Against High Blood Pressure
Current Pharmaceutical Design Oxytocin in the Heart Regeneration
Recent Patents on Cardiovascular Drug Discovery Catatonia: A Narrative Review
Central Nervous System Agents in Medicinal Chemistry Neuroprotective Strategies in Glaucoma
Current Pharmaceutical Design Melanoma
Current Cancer Therapy Reviews Central Nervous System Abnormalities in Fibromyalgia and Chronic Fatigue Syndrome: New Concepts in Treatment
Current Pharmaceutical Design Ruptured Renal Artery Aneurysm: Successful Endovascular Therapy with Stent-Graft Placement
Current Medical Imaging Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Sedation in PACU: The Role of Propofol
Current Drug Targets Therapeutic Use of Nitric Oxide Scavengers in Shock and Sepsis
Current Pharmaceutical Design Garlic for Cardiovascular Disease: Prevention or Treatment?
Current Pharmaceutical Design The Cardiorenal Syndrome: Pathophysiologic Crosstalk, Outcomes, and Treatment Targets
Cardiovascular & Hematological Disorders-Drug Targets Contribution of Catecholamine Reactive Intermediates and Oxidative Stress to the Pathologic Features of Heart Diseases
Current Medicinal Chemistry Antipsychotic and Antiepileptic Drugs in Bipolar Disorder: The Importance of Therapeutic Drug Monitoring
Current Medicinal Chemistry Restoring the Dysfunctional Endothelium
Current Pharmaceutical Design Potential Role of Rho-Associated Protein Kinase Inhibitors for Glaucoma Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Cysteine-Rich Mini-Proteins in Human Biology
Current Topics in Medicinal Chemistry Psoriatic Arthritis and its Novel Therapeutics
Current Rheumatology Reviews Pharmacological Risk Factors for Delirium after Cardiac Surgery: A Review
Current Neuropharmacology Cardiovascular Considerations of Remdesivir and Favipiravir in the Treatment of COVID-19
Cardiovascular & Hematological Disorders-Drug Targets